The International Atomic Energy Agency (IAEA) has launched a project to advance terbium-based radiopharmaceuticals for theranostics.
The project will strengthen production, harmonization, and access to terbium radioisotopes which have favorable decay properties and unique theranostic potential, according to the organization. IAEA highlighted terbium‑152 and terbium‑155 for imaging, and terbium‑161 and terbium‑149 for targeted radionuclide therapy.
Clinical and translational uptake of terbium-based radiopharmaceuticals remains at an early stage, the organization noted. IAEA's Coordinated Research Project on Advanced Theranostics Using Terbium Radioisotope Series (Tb Series) will provide a platform for knowledge exchange and technology transfer among member states.
The project aims to deliver standardized and validated production protocols, enhance technical expertise, improve the availability of terbium radioisotopes for research and strengthen international collaboration and dissemination of best practices, the organization said.
